Roche To Partner With Two European Biotechs On Oncology Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.
You may also be interested in...
BioInvent's Tie-Up With Cancer Research Technology Brings Some Relief From Pipeline Setbacks
Sweden's BioInvent forges links with researchers at Queen Mary, University of London, and Cancer Research Technology, the commercial arm of charity Cancer Research UK, to identify new therapeutic antibodies for oncology.
Genentech Expects Avastin Colon Cancer Data Ahead Of Schedule In 2009
Revised timeline for the C-08 trial does not change Genentech’s assessment of probability of success.
Genentech Acquires Preclinical Cardiovascular Antibody In Nearly $200 Million Deal
Firm will make $15 million up-front payment to BioInvent for North American rights to BI-204.